RENASANT BIO
LIVE

Serial Number

99490541

Owner

Renasant Bio, Inc.

Attorney

John Paul Oleksiuk

Filing Date

Nov 11, 2025

Add to watchlist:

No watchlists yet
View on USPTO

RENASANT BIO Trademark

Serial Number: 99490541

RENASANT BIO is a trademark filed by Renasant Bio, Inc. on November 11, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Renasant Bio, Inc.

2630 Bancroft Way
Berkeley, CA 94704

Entity Type: 03

Trademark Details

Filing Date

November 11, 2025

Registration Date

Not Registered

Published for Opposition

April 28, 2026

Goods & Services

Pharmaceutical research in the field of kidney diseases and disorders; Pharmaceutical research in the field of drug discovery for kidney diseases and disorders; Pharmaceutical research in the field of autosomal dominant polycystic kidney disease (ADPKD); Pharmaceutical research in the field of ion channel pharmacology and electrophysiology related to kidney diseases and disorders; Research and development in the field of kidney diseases and disorders; Medical and scientific research information in the field of kidney diseases and disorders; Scientific and technological services, namely, design and development of biological assays for scientific research purposes in the field of kidney disease drug discovery and development

Pharmaceutical preparations for the treatment of polycystic kidney disease, namely, autosomal dominant polycystic kidney disease (ADPKD); Pharmaceutical preparations for modulating polycystin ion channels for the treatment of autosomal dominant polycystic kidney disease (ADPKD); Pharmaceutical preparations for the treatment of kidney diseases and disorders; Pharmaceutical preparations for ion channel modulators for the treatment of kidney diseases and disorders; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, kidney diseases and disorders; Pharmaceutical preparations for the treatment of genetic kidney diseases

Filing History

EXTENSION OF TIME TO OPPOSE RECEIVED
May 26, 2026 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 28, 2026 NPUB
PUBLISHED FOR OPPOSITION
Apr 28, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 22, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 1, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 1, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 1, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 1, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 1, 2026 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 31, 2026 GNRN
NON-FINAL ACTION E-MAILED
Mar 31, 2026 GNRT
NON-FINAL ACTION WRITTEN
Mar 31, 2026 CNRT
ASSIGNED TO EXAMINER
Mar 20, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 12, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Nov 11, 2025 MAFR
NEW APPLICATION ENTERED
Nov 11, 2025 NWAP